ONEGLOBAL · NSE
One Global Service Provider Limited
₹538.8
+0.01% (+₹0.05)
Prev. close
₹538.75
Volume
4,470
Delivery %
85.9%
As of
21 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About One Global Service Provider Limited
One Global Service Provider Limited engages in the provision of healthcare services worldwide. The company offers diagnostic services, including anemia, antenatal, diabetes, diabetes monitoring, hypertension, kidney, and lipid profiles, as well as liver function tests; and healthcare services, such as end-to-end solutions in industrial occupational check-ups, population screening for non-communicable diseases, disease surveillance programs, electronic medical records and health registry, health analytics for predictive and preventive actions, and wellness programs for lifestyle diseases. It also provides laboratory services, such as biochemistry, microbiology, hematology and coagulation, histopathology and cytopathology, clinical pathology, molecular diagnostics, and serology. In addition, the company offers healthcare products, such as medical devices, equipment, medical consumables, and reagents through an online platform; and healthcare solutions comprising home-based health screening, public health data analytics, and home-based remote care services. Further, it involves in consultancy and development, requirements, designs, develops, tests, integrates, deploys, and maintains software/IT products; and purchases, sells, distributes licenses, resells, imports, exports IT and/or software products. The company was formerly known as Overseas Synthetics Limited. One Global Service Provider Limited was incorporated in 1992 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Pharmaceutical Retailers
CEO
Mr. Sanjay Lalbhadur Upadhaya
Headquarters
Mumbai
Employees
89
Website
1gsp.inExchange
View on NSE ↗Key stats
Market cap
₹1,092.74 Cr
P/E ratio (TTM)
14.3
Dividend yield
0.19%
EPS (TTM)
₹37.87
Beta (5Y monthly)
0.15
Shares float
25.58 L
EPS · quarter ended Jun 2026
₹7.32
Financial Performance
01 · Financials
Revenue for Mar 2022–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2021 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3.67 Cr | ₹6.08 Cr | ₹18.12 Cr | ₹63.01 Cr | ₹147.04 Cr | ₹498.18 Cr | |
| EBITDA | — | — | ₹1.65 Cr | ₹9.73 Cr | ₹25.95 Cr | ₹93.49 Cr |
| ₹2.33 Cr | ₹1.05 Cr | ₹1.38 Cr | ₹7.11 Cr | ₹18.47 Cr | ₹69.50 Cr | |
| Diluted EPS | ₹3.28 | ₹1.48 | ₹1.94 | ₹10.01 | ₹9.45 | ₹35.56 |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6.50 Cr | ₹8.51 Cr | ₹12.83 Cr | ₹31.81 Cr | ₹106.33 Cr | ₹254.24 Cr | |
| ₹33.93 L | ₹33.93 L | ₹33.93 L | ₹33.93 L | ₹33.93 L | ₹3.12 L | |
| Stockholders' equity | — | — | ₹7.29 Cr | ₹14.40 Cr | ₹71.72 Cr | ₹141.23 Cr |
Current assets, Trade receivables, Non-current assets, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2023-03-31, 2024-03-31, 2025-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2023-03-31, 2024-03-31, 2025-03-31, 2021-03-31, 2022-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2021-03-31, 2022-03-31 have no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹13.92 L | ₹1.21 Cr | ₹14.45 Cr | ₹-10.93 Cr | |
| Investing cash flow | — | — | ₹-16.12 L | ₹-1.14 L | ₹-11.07 L | ₹-20.72 L |
| — | — | ₹0 | ₹0 | ₹-71.05 L | ₹-30.82 L | |
| Capital expenditure | — | — | ₹-16.12 L | ₹-1.14 L | ₹-11.07 L | ₹-2.89 L |
| End cash position | — | — | ₹2.76 L | ₹1.23 Cr | ₹27.15 Cr | ₹15.71 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.41 L Cr | ₹1,868.9 | 36.5 | 5.27 | 13.7% | 0.06 | +11.9% | +12.9% |
| Divi's Laboratories Limited | ₹2.49 L Cr | ₹9,410.5 | 84.7 | 14.85 | 15.3% | 0.00 | +12.3% | +51.8% |
| Torrent Pharmaceuticals Limited | ₹1.84 L Cr | ₹4,970 | 77.5 | 21.95 | 25.8% | 1.79 | +21.5% | +36.9% |
| Apollo Hospitals Enterprise Limited | ₹1.29 L Cr | ₹8,912 | 61.7 | 13.57 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.25 L Cr | ₹683.85 | 188.8 | 14.29 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,161 | 25.8 | 4.27 | 18.6% | 0.46 | +18.4% | +11.9% |
| Cipla Limited | ₹1.13 L Cr | ₹1,386.1 | 33.4 | 3.27 | 11.3% | 0.02 | +2.1% | -12.0% |
| Laurus Labs Limited | ₹1.06 L Cr | ₹2,017.5 | 96.2 | 19.92 | 16.8% | 0.48 | +22.0% | +116.4% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Aurobindo Pharma Limited | ₹99,770.53 Cr | ₹1,713.4 | 27.1 | 2.63 | 9.2% | 0.21 | +6.4% | +53.1% |
| Dr. Reddy's Laboratories Limited | ₹98,709.15 Cr | ₹1,198.3 | 29.8 | 2.62 | 11.4% | 0.21 | +3.2% | -9.3% |
| One Global Service Provider Limited | ₹1,036.56 Cr | ₹538.8 | 14.0 | 7.34 | 49.2% | 0.00 | +238.8% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 25
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.